Terns Pharmaceuticals TERN

$ 5.73 2.23%

Quarterly report 2024-Q3
added 11-12-2024

Terns Pharmaceuticals Income Statement 2011-2024 | TERN

Annual Income Statement Terns Pharmaceuticals

	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Market Cap	478 M	326 M	142 M	-	-	-	-	-	-	-	-	-	-
Shares	71.3 M	36 M	22.7 M	-	-	-	-	-	-	-	-	-	-
Historical Prices	6.71	9.04	6.27	-	-	-	-	-	-	-	-	-	-
Net Income	-90.2 M	-60.3 M	-50.2 M	-40.1 M	-68.6 M	-17.7 M	-	-	-	-	-	-	-
Revenue	-	-	1 M	-	-	-	-	-	-	-	-	-	-
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Income	-103 M	-62 M	-49.9 M	-37 M	-	-	-	-	-	-	-	-	-
Interest Expense	-314 K	-68 K	40 K	99 K	-	-	-	-	-	-	-	-	-
EBITDA	-102 M	-61.5 M	-49.3 M	-36.6 M	-70 M	-18.4 M	-	-	-	-	-	-	-
Operating Expenses	-	-	-	37 M	-	-	-	-	-	-	-	-	-
General and Administrative Expenses	39.1 M	22.4 M	19.5 M	9 M	8.66 M	3.9 M	-	-	-	-	-	-	-

All numbers in USD currency

Quarterly Income Statement Terns Pharmaceuticals

	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Shares	77.8 M	74.5 M	74.4 M	64.6 M	71.5 M	71.4 M	69.8 M	53.7 M	38.5 M	25.3 M	25.3 M	25.3 M	25.1 M	25.1 M	15.2 M	338 K	302 K	293 K	216 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	-21.9 M	-22.7 M	-22.4 M	-	-29.8 M	-17.9 M	-21.5 M	-	-16.8 M	-13.9 M	-13.8 M	-	-11.8 M	-10.7 M	-13.3 M	-	-11.4 M	-9.69 M	-9 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Income	-24.9 M	-25.5 M	-25.4 M	-	-33.2 M	-21.2 M	-24.2 M	-	-17.3 M	-14.1 M	-13.8 M	-	-11.9 M	-10.8 M	-13.3 M	-	-8.74 M	-10.1 M	-9.42 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest Expense	-32 K	-14 K	-12 K	-	-5 K	-60 K	-4 K	-	-14 K	-54 K	4 K	-	4 K	39 K	-13 K	-	-387 K	250 K	167 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
EBITDA	-	-	-25.4 M	-	-	-	-24.1 M	-	-16.9 M	-13.8 M	-13.7 M	-	-11.5 M	-10.5 M	-13.1 M	-	-8.45 M	-9.91 M	-9.34 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
General and Administrative Expenses	9.77 M	7.18 M	6.86 M	-	18.4 M	7.01 M	7.1 M	-	5.13 M	5.42 M	5.69 M	-	4.72 M	4.86 M	4.56 M	-	3.33 M	2.49 M	2.18 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency